Med Men Enterprises, Inc. MMNFF
We take great care to ensure that the data presented and summarized in this overview for MedMen Enterprises, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MMNFF
View all-
Jackson Wealth Management, LLC50KShares$00.0% of portfolio
-
First National Trust CO10.5KShares$00.0% of portfolio
-
Hbc Financial Services, Pllc5KShares$00.0% of portfolio
-
Ancora Advisors, LLC Cleveland, OH234Shares$00.0% of portfolio
-
Main Street Group, LTD Glen Allen, VA170Shares$00.0% of portfolio
-
Heritage Wealth Advisors125Shares$00.0% of portfolio
-
Strategic Investment Solutions, Inc. /Il Orland Park, IL20Shares$00.0% of portfolio
Latest Institutional Activity in MMNFF
Top Purchases
Top Sells
About MMNFF
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, distributes, and retails recreational and medicinal cannabis under the MedMen Red and LuxLyte brand names. As of December 25, 2021, it operated 29 stores in California, Florida, Nevada, Illinois, Arizona, Massachusetts, and New York. MedMen Enterprises Inc. is headquartered in Culver City, California.
Insider Transactions at MMNFF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 25
2023
|
Melony Valleau CAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,102,041
+50.0%
|
-
|
|
Jul 24
2023
|
Amit Pandey CFO |
BUY
Grant, award, or other acquisition
|
Direct |
13,157,895
+50.0%
|
$0
$0.02 P/Share
|
|
Apr 19
2022
|
Cameron Dovi Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,449
+12.72%
|
-
|
|
Apr 19
2022
|
Errol Schweizer Director |
BUY
Grant, award, or other acquisition
|
Direct |
106,028
+7.92%
|
-
|
|
Apr 19
2022
|
Edward J Record Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,449
+47.53%
|
-
|
|
Apr 19
2022
|
David Hsu Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,449
+47.53%
|
-
|
|
Apr 19
2022
|
Melvin Elias Director |
BUY
Grant, award, or other acquisition
|
Direct |
160,775
+13.4%
|
-
|
|
Dec 09
2021
|
Melvin Elias Director |
BUY
Grant, award, or other acquisition
|
Direct |
160,824
+15.48%
|
-
|
|
Dec 09
2021
|
David Hsu Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,924
+50.0%
|
-
|
|
Dec 09
2021
|
Edward J Record Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,924
+50.0%
|
-
|
|
Dec 09
2021
|
Errol Schweizer Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,499
+11.3%
|
-
|
|
Dec 09
2021
|
Cameron Dovi Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,499
+14.58%
|
-
|
|
Aug 29
2021
|
Michael Jay Lane CIO |
BUY
Grant, award, or other acquisition
|
Direct |
781,809
+26.62%
|
-
|
|
Aug 29
2021
|
Reece Alan Fulgham Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
454,129
+50.0%
|
-
|
|
Aug 29
2021
|
Timothy Bossidy Interim COO |
BUY
Grant, award, or other acquisition
|
Direct |
850,036
+28.73%
|
-
|
|
Aug 29
2021
|
Thomas Jerome Lynch CEO |
BUY
Grant, award, or other acquisition
|
Direct |
850,036
+24.67%
|
-
|
|
Aug 29
2021
|
Tracy Mccourt Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
477,417
+50.0%
|
-
|
|
Aug 27
2021
|
Nicole Christoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
286,998
+33.95%
|
-
|
|
Aug 27
2021
|
Melvin Elias Director |
BUY
Grant, award, or other acquisition
|
Direct |
307,423
+29.99%
|
-
|
|
Aug 27
2021
|
Albert Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
286,998
+28.78%
|
-
|